Is ALMDP.PA stock a buy after today’s intraday move?

ALMDP.PA stock shows a short‑term oversold bounce, but fundamentals are weak. Consider small, tactical positions with a stop below €0.30 and a target near €0.50 or €0.60. This is high‑risk, not a long‑term buy without clinical or funding updates.

What are the main catalysts for ALMDP.PA stock?

Catalysts include clinical trial updates for NanoLithium (NP03), funding or partnership announcements, and improved Healthcare sector flows. Any positive clinical news can produce fast moves given low float and elevated intraday volume.

How does Meyka AI arrive at the ALMDP.PA stock grade?

Meyka AI rates ALMDP.PA using a multi‑factor model: S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. The current score is **64.99** (Grade B, HOLD), informational only, not investment advice.

What stop and target suit an oversold bounce trade on ALMDP.PA stock?

For an oversold bounce, use a tight stop near **€0.30** and scale targets: first at **€0.50**, second at **€0.60**. Adjust size for risk tolerance and exit quickly on negative company news.

EU Stocks

ALMDP.PA stock Medesis Pharma EURONEXT trading €0.35 intraday 13 Mar 2026: watch oversold bounce to €0.60

ByDanny Kontos March 13, 2026

ALMDP.PA stock, Medesis Pharma S.A. on EURONEXT, trades at €0.35 intraday on 13 Mar 2026 with an unusual volume spike of 149,072 shares. The price sits above the day low €0.34 and below the 50-day average €0.37, setting a classic oversold bounce scenario for short-term traders. We examine liquidity, fundamentals, technical triggers, and a model price target to frame risk and reward for the oversold bounce trade.